Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial

Area of Science:

• Pharmacology
• Urology

Background:

• Overactive bladder (OAB) and urge incontinence significantly impact quality of life.
• Trospium chloride, a peripheral antimuscarinic agent, offers potential benefits due to its lack of central nervous system effects and minimal drug-drug interactions.
• Its efficacy in treating OAB symptoms warrants investigation.

Purpose of the Study:

• To evaluate the effectiveness of trospium chloride in managing symptoms of overactive bladder (OAB) with urge incontinence.
• To assess trospium chloride's impact on voiding frequency, incontinence episodes, and quality of life.

Main Methods:

• A 12-week, multicenter, double-blind, placebo-controlled trial randomized 523 patients with OAB and urge incontinence.
• Patients received either 20 mg trospium chloride twice daily or a placebo.
• Primary endpoints included changes in average toilet voids and urge incontinence episodes per 24 hours.

Main Results:

• Trospium chloride significantly reduced the average frequency of toilet voids and urge incontinence episodes compared to placebo.
• The treatment led to a significant increase in average volume per void and decreased urge severity and daytime frequency.
• Benefits were observed by week 1 and sustained throughout the 12-week study period, with improvements in quality of life measures.

Conclusions:

• Trospium chloride demonstrated sustained effectiveness in improving OAB symptoms, including reduced voiding frequency and incontinence episodes.
• The medication was well-tolerated and improved patients' overall quality of life.
• Early and sustained efficacy makes trospium chloride a valuable option for OAB management.